National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 18 of 66

COMPLETED Phase 2

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
TERMINATED Phase 1

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT03772925
COMPLETED Phase 1

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

NCT03958656
COMPLETED Phase 1

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

NCT03905135
COMPLETED Phase 2

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952
TERMINATED Phase 2

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

NCT03785210
COMPLETED Phase 1

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT03813147
TERMINATED Phase 1

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
TERMINATED Phase 1

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

NCT03300544
TERMINATED Phase 1

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

NCT03724084
TERMINATED Phase 3

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

NCT03199885
TERMINATED Phase 2

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827
TERMINATED Early Phase 1

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

NCT03382574
TERMINATED Phase 2

Sunitinib in Sarcomas of the Central Nervous System

NCT03641326
COMPLETED Phase 2

Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome

NCT03648879
COMPLETED

Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers

NCT03863795
COMPLETED NA

Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers

NCT03538587
TERMINATED Phase 1

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
COMPLETED Phase 2

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

NCT03253679
COMPLETED Phase 2

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

NCT03027388
COMPLETED Phase 1

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

NCT03738228
COMPLETED Phase 2

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

NCT03602586
COMPLETED Phase 2

M7824 in People With Recurrent Respiratory Papillomatosis

NCT03707587
TERMINATED Phase 2

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

NCT03644550
COMPLETED Phase 1

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT03309878
COMPLETED NA

Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials

NCT03531814
COMPLETED Phase 1

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473
COMPLETED

DoD-NCI TRICARE Feasibility Study

NCT02339025
COMPLETED Phase 2

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
COMPLETED

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch

NCT03627208
COMPLETED Phase 1

Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

NCT03300570
COMPLETED Phase 1

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

NCT03481816
COMPLETED Phase 2

Olaparib in People With Malignant Mesothelioma

NCT03531840
TERMINATED Phase 1

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

NCT03107780
COMPLETED Phase 1

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744
COMPLETED Phase 1

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

NCT03217266
COMPLETED Phase 1

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
TERMINATED Phase 1

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

NCT03031730
COMPLETED Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
TERMINATED Phase 2

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

NCT02917629
TERMINATED Phase 1

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

NCT03345784
COMPLETED

Questionnaire Pre-Test Study

NCT03248635
TERMINATED

Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

NCT02706652
COMPLETED Phase 2

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03382561
TERMINATED Phase 1

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

NCT03480152
TERMINATED Phase 1

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

NCT03451773
COMPLETED Phase 2

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

NCT03468985
COMPLETED Phase 1

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

NCT03493945
TERMINATED Phase 1

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

NCT03190967
TERMINATED Phase 1

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724
← Previous Page 18 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.